Prediction of recurrence in prostate cancer following radiotherapy: Value of biomarkers microvessel density, MIB-1, P-53, BCL2, and Bax

Abstract

Background. Standard traditional parameters relied on for estimating the risk of disease recurrence after curative radiotherapy in prostate cancer are stage, Gleason score and PSA. Objectives. To elucidate the prognostic role of biomarkers: P-53, MIB-1, MVD, Bax and BCL2 in prostate cancer. Method. Cox proportional hazard model was used to estimate the risk of disease progression associated with these biomarkers and develop models based on traditional parameters only or incorporating biomarkers. Models were compared for their predictive potential using Akaike information criteria and concordance index. Results. Statistically significant associations were found between all biomarkers and risk of progression. MVD, Bax and Bax/BCL2 were independent predictors of outcome. Models incorporating biomarkers were superior to the traditional one in identifying patients at risk of local progression. Conclusions. Biomarkers may be useful in forecasting the risk of local recurrence following radiotherapy in prostate cancer patients. The results require validation in a separate cohort.